Mantle Cell Lymphoma
Conditions
Keywords
Mantle Cell Lymphoma, Rituximab, Lenalidomide, Bortezomib, Phase 1/2
Brief summary
This is a Phase I/II multicenter, open-label, dose-escalation study of rituximab, bortezomib, and lenalidomide in the first-line or second-line treatment of patients with Mantle Cell Lymphoma (MCL).
Detailed description
The combination of lenalidomide with bortezomib has not been studied in patients with MCL, but feasibility and tolerability has been demonstrated in patients with multiple myeloma. Thus, almost every 2-drug combination of rituximab, lenalidomide, and bortezomib has been tested, or is being tested. We hypothesize that all three drugs are important in MCL, and therefore propose to combine all 3 agents (rituximab, bortezomib, and lenalidomide) in a schedule that is convenient to lymphoma patients. Approximately 18 patients may be enrolled in the Phase I portion of the study. Approximately 45 patients are planned for enrollment in Phase II.
Interventions
DRUGRituximab
DL 1, DL 2, and DL 3: 375 mg/m2 IV Days 1, 8, and 15; Cycles 2-6: 375 mg/m2 IV Day 1 Same for DL-1.
DRUGBortezomib
DL 1, DL 2, and DL 3: 1.3 mg/m2 IV Days 1, 4, 8, and 11 Same for DL-1.
DRUGLenalidomide
DL 1: 15 mg PO daily Days 1-14 followed by 7 days of rest DL 2: 20 mg PO daily Days 1-14 followed by 7 days of rest DL 3: 25 mg PO daily Days 1-14 followed by 7 days of rest DL-1: 10 mg PO daily Days 1-14 followed by 7 days of rest
Sponsors
Millennium Pharmaceuticals, Inc.
Celgene
SCRI Development Innovations, LLC
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. All study participants must be registered into the Mandatory Revlimid Risk Evaluation and Mitigation Strategies (REMS) Program, and be willing and able to comply with the requirements of the REMS program. 2. Histology: biopsy-proven mantle cell lymphoma (MCL). 3. Prior therapy: both newly diagnosed patients and relapsed or refractory patients who have received one prior therapy are eligible. Patients who have previously received high-dose chemotherapy with peripheral stem cell support are eligible. 4. Presence of at least one lymph node evaluable or mass measurable for response. 5. Platelets ≥ 75,000/µL and absolute neutrophil count (ANC) ≥ 1,000/µL within 14 days of study registration (unless the treating physician deems the neutropenia is related to bone marrow involvement, then an ANC of \> 750/mm3 is allowed). 6. Renal function assessed by calculated creatinine clearance between ≥ 30 ml/min and ˂60ml/min by the Cockcroft-Gault method within 14 days of study registration 7. Total bilirubin ≤ 1.5x upper limit of normal (ULN), aspartate transaminase (AST) (SGOT) and alanine transaminase (ALT) (SGOT) ≤ 3 x ULN 8. Eastern Cooperative Oncology Group (ECOG) performance of 0, 1, or 2. 9. Recovery from any previous treatment therapy. 10. Females of childbearing potential (FCBP) must adhere to the scheduled pregnancy testing required in the Revlimid REMS® program, must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10-14 days prior and again within 24 hours of starting lenalidomide for Cycle 1 (prescriptions must be filled within 7 days as required by Revlimid REMS Program) and must either commit to continued abstinence from heterosexual intercourse or begin two acceptable methods of birth control, one highly effective method and one additional effective method at the same time, at least 28 days before she starts taking lenalidomide. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy. 11. All study participants must be registered into the mandatory Revlimid REMS® program, and be willing and able to comply with the requirements of Revlimid REMS® program. 12. Ability to understand and willingness to voluntarily sign a written informed consent document before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.
Exclusion criteria
1. Patient has \>1.5 x ULN total bilirubin. 2. Peripheral neuropathy ≥ CTCAE grade 2. 3. Relapsed or refractory patients who have received more than one prior therapy. 4. Pregnant or breastfeeding females. (Lactating females must agree not to breastfeed while taking lenalidomide.) 5. Female patients who have a positive serum pregnancy test during the screening period, or a positive urine pregnancy test on Day 1 before first dose of study drug, if applicable. 6. Thrombolic or embolic events (such as a cerebrovascular accident, including transient ischemic attacks) within the past 6 months. 7. Pulmonary hemorrhage/bleeding event ≥ CTCAE grade 2 within 28 days of the first dose of study drug. 8. Any other hemorrhage/bleeding event ≥ CTCAE grade 3 ≤ 28 days of the first dose of study drug 9. Known brain metastasis. Patients with neurological symptoms must undergo a CT scan/MRI of the brain to exclude brain metastasis. 10. Central nervous system (CNS) involvement by lymphoma at time of enrollment. 11. Other medical conditions or psychiatric illness that would potentially interfere with patient participation in this trial. 12. A second malignancy, other than basal cell carcinoma of the skin or in situ carcinoma of the cervix, unless the tumor was treated with curative intent at least 2 years previously. 13. Previous evidence of hypersensitivity to bortezomib, boron, mannitol, thalidomide, (and development of erythema nodosum if characterized by a desquamating rash), or rituximab (true anaphylaxis, not a rituximab-infusion reaction). 14. Known human immunodeficiency virus (HIV) infection or chronic hepatitis A, B, or C. Patients who are HIV positive or who are positive for chronic hepatitis A, B, or C will be excluded due to increased risk for bone marrow suppression and other toxicities. 15. Active, clinically serious infection \> CTCAE grade 2. Patients may be eligible upon resolution of the infection. 16. Evidence or history of bleeding diathesis or coagulopathy. 17. Major surgery, open biopsy, or significant traumatic injury within 28 days of the first dose of study drug. 18. Use of any other standard chemotherapy, radiation therapy, or experimental drug for the treatment of MCL within 28 days of starting treatment. 19. Any condition that impairs a patient's ability to swallow whole pills. Impairment of gastrointestinal function (GI) or GI disease that may significantly alter the absorption of lenalidomide (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection). 20. Patients with grade 3/4 cardiac problems, as defined by the New York Heart Association (NYHA) criteria or any of the following: * History of uncontrolled or symptomatic angina * History of arrhythmias requiring medications, or clinically significant, with the exception of asymptomatic atrial fibrillation requiring anticoagulation * Myocardial infarction \< 6 months from study entry * Uncontrolled or symptomatic congestive heart failure * Ejection fraction below the institutional normal limit * Electrocardiographic evidence of acute ischemia or active conduction system * Any other cardiac condition that, in the opinion of the treatment physician, would make this protocol unreasonably hazardous for the patient * Prior to study entry, any ECG abnormality at screening has to be documented by the investigator as not medically relevant. 21. Uncontrolled hypertension (systolic blood pressure \[BP\] \> 180 or diastolic BP \> 100mm Hg) or uncontrolled cardiac arrhythmias. 22. Any prior use of lenalidomide.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum Tolerated Dose of Lenalidomide Combined With Bortezomib and Rituximab in Phase I Participants | Collected from day of first dose to the end of the first treatment cycle, up to 21 days | Determination of the maximum tolerated dose (MTD) of lenalidomide combined with bortezomib and rituximab, defined as the highest dose at which ≤1 of 6 patients experiences a dose-limiting toxicity according to the NCI CTCAE v. 4.03. MTD of Lenalidomide was tested, included with 1.3 mg/m2 subcutaneous (D1, 4, 8, 11) bortezomib, 375 mg/m2 (D1, 8, 15 of Cycle 1, D1 on subsequent cycles) rituximab. Three dose limiting toxicities were reported in two patients (grade 4 neutropenia and grade 3 neuropathy, grade 3 rash) |
| Incidence of Non-Serious Adverse Events as a Measure of Safety and Tolerability, Phase II | Collected from day of first dose to 30 days after the last dose of study medication, a maximum of 18 weeks and 30 days after last study treatment | A count of affected participants with non-serious adverse events (regardless of relationship to study treatments) occurring in \>= 15% of treated patients enrolled in the Phase II section of the study. Lenalidomide DL-1 dose (10 mg orally, once daily (PO QD)) Day 1-14 followed by 7 days of rest, Rituximab 375 mg/m2 IV Days 1, 8, and 15 of Cycle 1; Cycles 2-6: 375 mg/m2 IV Day 1, Bortezomib 1.3 mg/m2 subcutaneous Days 1, 4, 8, and 11 for Cycles 1-6 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to Best Response of Phase I and Phase II Participants | Every 3 months (+/- 2 weeks) after discontinuation of study treatment for 2 years | Measured from the time of study entry to the documented beginning of response (CR or PR). This is measured in responders per Non-Hodgkin's Lymphoma Revised Response Criteria for Malignant Lymphoma (Cheson et al. 2007.) CR: complete disappearance of detectable clinical evidence of disease and disease-related symptoms; PR: 50% or greater decrease in sum of product of diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses, no increase in size of other nodes, liver or spleen, no new disease sites, patients with CR and persistent morphologic bone marrow involvement. Time to Best Response will be examined using time-to-event analysis methods. Kaplan-Meier figures will be generated and the log-rank test will be used to examine differences existing between various levels of stratification. |
| Time to Best Response of Previously Treated and Previously Untreated Participants | Every 3 months (+/- 2 weeks) after discontinuation of study treatment for 2 years | Measured from the time of study entry to the documented beginning of response (CR or PR). This is measured in responders per Non-Hodgkin's Lymphoma Revised Response Criteria for Malignant Lymphoma (Cheson et al. 2007.) CR: complete disappearance of detectable clinical evidence of disease and disease-related symptoms; PR: 50% or greater decrease in sum of product of diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses, no increase in size of other nodes, liver or spleen, no new disease sites, patients with CR and persistent morphologic bone marrow involvement. |
| Duration of Response (DoR) of Phase I and Phase II Participants | Every 3 months (+/- 2 weeks) after discontinuation of study treatment for 2 years or until documented disease progression | Measured from the documented beginning of response (CR or PR) to the time of relapse. This is measured in responders per Non-Hodgkin's Lymphoma Revised Response Criteria for Malignant Lymphoma (Cheson et al. 2007.) CR: complete disappearance of detectable clinical evidence of disease and disease-related symptoms; PR: 50% or greater decrease in sum of product of diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses, no increase in size of other nodes, liver or spleen, no new disease sites, patients with CR and persistent morphologic bone marrow involvement. Duration of Response will be examined using time-to-event analysis methods. Kaplan-Meier figures will be generated and the log-rank test will be used to examine differences existing between various levels of stratification. |
| Duration of Response (DoR) of Previously Treated and Previously Untreated Participants | Every 3 months (+/- 2 weeks) after discontinuation of study treatment for 2 years or until documented disease progression | Measured from the documented beginning of response (CR or PR) to the time of relapse. This is measured in responders per Non-Hodgkin's Lymphoma Revised Response Criteria for Malignant Lymphoma (Cheson et al. 2007.) CR: complete disappearance of detectable clinical evidence of disease and disease-related symptoms; PR: 50% or greater decrease in sum of product of diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses, no increase in size of other nodes, liver or spleen, no new disease sites, patients with CR and persistent morphologic bone marrow involvement. |
| Overall Response Rate (ORR) of Phase I and Phase II Participants | Every 6 weeks until treatment discontinuation then every 3 months thereafter, projected average 24 months | Response to treatment (Complete Response (CR) or Partial Response (PR)) determined using Non-Hodgkin's Lymphoma Revised Response Criteria for Malignant Lymphoma (Cheson et al. 2007.) CR: complete disappearance of all detectable clinical evidence of disease and disease-related symptoms; PR: 50% or greater decrease in sum of the product of the diameters (SPD) of up to 6 of the largest dominant nodes or extranodal masses, no increase in the size of other nodes, liver or spleen, no new sites of disease, patients who achieve CR but have persistent morphologic bone marrow involvement; Stable Disease (SD): failing to attain PR or CR, but not fulfilling criteria for progressive disease; Progressive Disease (PD)/Relapse: appearance of new lesions more than 1.5 cm in any axis, 50% or greater increase from nadir SPD of any previously involved sites, 50% or greater increase in the longest diameter of any single previously identified node or extranodal mass more than 1 cm in short axis. |
| Progression Free Survival (PFS) of Previously Treated and Previously Untreated Participants | Every 3 months (+/- 2 weeks) after discontinuation of study treatment for 2 years, then every 6 months after documented disease progression | Defined as the time from entry onto study until lymphoma progression or death from any cause. Progression Free Survival will be examined using time-to-event analysis methods. Kaplan-Meier figures will be generated and the log-rank test will be used to examine differences existing between various levels of stratification. |
| Overall Survival of Phase I and Phase II Participants | Every 3 months (+/- 2 weeks) after discontinuation of study treatment for 2 years, then every 6 months after documented disease progression | Defined as the date of study entry to the date of death. Overall Survival will be examined using time-to-event analysis methods. Kaplan-Meier figures will be generated and the log-rank test will be used to examine differences existing between various levels of stratification |
| Overall Survival of Previously Treated and Previously Untreated Participants | Every 3 months (+/- 2 weeks) after discontinuation of study treatment for 2 years, then every 6 months after documented disease progression | Defined as the date of study entry to the date of death. Overall Survival will be examined using time-to-event analysis methods. Kaplan-Meier figures will be generated and the log-rank test will be used to examine differences existing between various levels of stratification |
| Progression Free Survival (PFS) of Phase I and Phase II Participants | Every 3 months (+/- 2 weeks) after discontinuation of study treatment for 2 years, then every 6 months after documented disease progression | Defined as the time from entry onto study until lymphoma progression or death from any cause. Progression Free Survival will be examined using time-to-event analysis methods. Kaplan-Meier figures will be generated and the log-rank test will be used to examine differences existing between various levels of stratification. |
| Overall Response Rate (ORR) of Previously Treated and Previously Untreated Participants | Every 6 weeks until treatment discontinuation then every 3 months thereafter, projected average 24 months | Response to treatment (Complete Response (CR) or Partial Response (PR)) determined using Non-Hodgkin's Lymphoma Revised Response Criteria for Malignant Lymphoma (Cheson et al. 2007.) CR: complete disappearance of all detectable clinical evidence of disease and disease-related symptoms; PR: 50% or greater decrease in sum of the product of the diameters (SPD) of up to 6 of the largest dominant nodes or extranodal masses, no increase in the size of other nodes, liver or spleen, no new sites of disease, patients who achieve CR but have persistent morphologic bone marrow involvement; Stable Disease (SD): failing to attain PR or CR, but not fulfilling criteria for progressive disease; Progressive Disease (PD)/Relapse: appearance of new lesions more than 1.5 cm in any axis, 50% or greater increase from nadir SPD of any previously involved sites, 50% or greater increase in the longest diameter of any single previously identified node or extranodal mass more than 1 cm in short axis. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Phase I - Lenalidomide 15mg PO QD Cycle 1: rituximab 375 mg/m2 intravenously (IV) on Days 1, 8, and 15; bortezomib 1.3 mg/ m2 subcutaneously (SC) on Days 1, 4, 8, and 11; and lenalidomide 15 mg by mouth (PO) daily on Days 1-14. Cycles 2 - 6: rituximab 375 mg/m2 IV on Day 1; bortezomib 1.3 mg/ m2 SC on Days 1, 4, 8, and 11; and lenalidomide 15 mg PO daily on Days 1 14. . | 5 |
| Phase I - Lenalidomide 10mg PO QD Cycle 1: rituximab 375 mg/m2 intravenously (IV) on Days 1, 8, and 15; bortezomib 1.3 mg/ m2 subcutaneously (SC) on Days 1, 4, 8, and 11; and lenalidomide 10 mg by mouth (PO) daily on Days 1-14. Cycles 2 - 6: rituximab 375 mg/m2 IV on Day 1; bortezomib 1.3 mg/ m2 SC on Days 1, 4, 8, and 11; and lenalidomide 10 mg PO daily on Days 1 14. | 8 |
| Phase II - Lenalidomide 10mg PO QD Cycle 1: rituximab 375 mg/m2 intravenously (IV) on Days 1, 8, and 15; bortezomib 1.3 mg/ m2 subcutaneously (SC) on Days 1, 4, 8, and 11; and lenalidomide 10 mg by mouth (PO) daily on Days 1-14. Cycles 2 - 6: rituximab 375 mg/m2 IV on Day 1; bortezomib 1.3 mg/ m2 SC on Days 1, 4, 8, and 11; and lenalidomide 10 mg PO daily on Days 1 14. | 26 |
| Total | 39 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Adverse Event | 0 | 4 | 7 |
| Overall Study | Death | 0 | 1 | 2 |
| Overall Study | Disease Progression | 0 | 0 | 1 |
Baseline characteristics
| Characteristic | Phase I - Lenalidomide 15mg PO QD | Phase I - Lenalidomide 10mg PO QD | Phase II - Lenalidomide 10mg PO QD | Total |
|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 2 Participants | 6 Participants | 19 Participants | 27 Participants |
| Age, Categorical Between 18 and 65 years | 3 Participants | 2 Participants | 7 Participants | 12 Participants |
| Age, Continuous | 60 years | 69 years | 69 years | 69 years |
| Age, Customized Previously Treated : <= 18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Customized Previously Treated : >= 65 years | 1 Participants | 1 Participants | 5 Participants | 7 Participants |
| Age, Customized Previously Treated : Between 18 and 65 years | 3 Participants | 0 Participants | 0 Participants | 3 Participants |
| Age, Customized Previously Untreated : <= 18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Customized Previously Untreated : >= 65 years | 1 Participants | 5 Participants | 14 Participants | 20 Participants |
| Age, Customized Previously Untreated : Between 18 and 65 years | 0 Participants | 2 Participants | 7 Participants | 9 Participants |
| Gender Female | 1 Participants | 2 Participants | 7 Participants | 10 Participants |
| Gender Male | 4 Participants | 6 Participants | 19 Participants | 29 Participants |
| Previous Treatment for Mantle Cell Lymphoma (MCL) Previously Treated | 4 participants | 1 participants | 5 participants | 10 participants |
| Previous Treatment for Mantle Cell Lymphoma (MCL) Previously Untreated | 1 participants | 7 participants | 21 participants | 29 participants |
| Region of Enrollment United States | 5 participants | 8 participants | 26 participants | 39 participants |
| Sex/Gender, Customized Previously Treated : Female | 1 Participants | 1 Participants | 2 Participants | 4 Participants |
| Sex/Gender, Customized Previously Treated : Male | 3 Participants | 0 Participants | 3 Participants | 6 Participants |
| Sex/Gender, Customized Previously Untreated : Female | 0 Participants | 1 Participants | 5 Participants | 6 Participants |
| Sex/Gender, Customized Previously Untreated : Male | 1 Participants | 6 Participants | 16 Participants | 23 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — |
| other Total, other adverse events | 5 / 5 | 8 / 8 | 25 / 26 |
| serious Total, serious adverse events | 2 / 5 | 6 / 8 | 13 / 26 |
Outcome results
Primary
Incidence of Non-Serious Adverse Events as a Measure of Safety and Tolerability, Phase II
A count of affected participants with non-serious adverse events (regardless of relationship to study treatments) occurring in \>= 15% of treated patients enrolled in the Phase II section of the study. Lenalidomide DL-1 dose (10 mg orally, once daily (PO QD)) Day 1-14 followed by 7 days of rest, Rituximab 375 mg/m2 IV Days 1, 8, and 15 of Cycle 1; Cycles 2-6: 375 mg/m2 IV Day 1, Bortezomib 1.3 mg/m2 subcutaneous Days 1, 4, 8, and 11 for Cycles 1-6
Time frame: Collected from day of first dose to 30 days after the last dose of study medication, a maximum of 18 weeks and 30 days after last study treatment
Population: Includes patients that were enrolled in the Phase II section of the study
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Phase I Participants (10 mg/15 mg Lenalidomide) | Incidence of Non-Serious Adverse Events as a Measure of Safety and Tolerability, Phase II | Rash | 19 participants |
| Phase I Participants (10 mg/15 mg Lenalidomide) | Incidence of Non-Serious Adverse Events as a Measure of Safety and Tolerability, Phase II | Fatigue | 18 participants |
| Phase I Participants (10 mg/15 mg Lenalidomide) | Incidence of Non-Serious Adverse Events as a Measure of Safety and Tolerability, Phase II | Thrombocytopenia | 16 participants |
| Phase I Participants (10 mg/15 mg Lenalidomide) | Incidence of Non-Serious Adverse Events as a Measure of Safety and Tolerability, Phase II | Leukopenia | 13 participants |
| Phase I Participants (10 mg/15 mg Lenalidomide) | Incidence of Non-Serious Adverse Events as a Measure of Safety and Tolerability, Phase II | Nausea | 12 participants |
| Phase I Participants (10 mg/15 mg Lenalidomide) | Incidence of Non-Serious Adverse Events as a Measure of Safety and Tolerability, Phase II | Diarrhea | 11 participants |
| Phase I Participants (10 mg/15 mg Lenalidomide) | Incidence of Non-Serious Adverse Events as a Measure of Safety and Tolerability, Phase II | Edema | 11 participants |
| Phase I Participants (10 mg/15 mg Lenalidomide) | Incidence of Non-Serious Adverse Events as a Measure of Safety and Tolerability, Phase II | Hyperglycemia | 11 participants |
| Phase I Participants (10 mg/15 mg Lenalidomide) | Incidence of Non-Serious Adverse Events as a Measure of Safety and Tolerability, Phase II | Peripheral Neuropathy | 10 participants |
| Phase I Participants (10 mg/15 mg Lenalidomide) | Incidence of Non-Serious Adverse Events as a Measure of Safety and Tolerability, Phase II | Neutropenia | 10 participants |
| Phase I Participants (10 mg/15 mg Lenalidomide) | Incidence of Non-Serious Adverse Events as a Measure of Safety and Tolerability, Phase II | Hypoalbuminemia | 10 participants |
| Phase I Participants (10 mg/15 mg Lenalidomide) | Incidence of Non-Serious Adverse Events as a Measure of Safety and Tolerability, Phase II | Constipation | 9 participants |
| Phase I Participants (10 mg/15 mg Lenalidomide) | Incidence of Non-Serious Adverse Events as a Measure of Safety and Tolerability, Phase II | Hypocalcemia | 9 participants |
| Phase I Participants (10 mg/15 mg Lenalidomide) | Incidence of Non-Serious Adverse Events as a Measure of Safety and Tolerability, Phase II | Pain in Extremity | 9 participants |
| Phase I Participants (10 mg/15 mg Lenalidomide) | Incidence of Non-Serious Adverse Events as a Measure of Safety and Tolerability, Phase II | Anemia | 8 participants |
| Phase I Participants (10 mg/15 mg Lenalidomide) | Incidence of Non-Serious Adverse Events as a Measure of Safety and Tolerability, Phase II | Cough | 8 participants |
| Phase I Participants (10 mg/15 mg Lenalidomide) | Incidence of Non-Serious Adverse Events as a Measure of Safety and Tolerability, Phase II | Fever | 8 participants |
| Phase I Participants (10 mg/15 mg Lenalidomide) | Incidence of Non-Serious Adverse Events as a Measure of Safety and Tolerability, Phase II | Dehydration | 7 participants |
| Phase I Participants (10 mg/15 mg Lenalidomide) | Incidence of Non-Serious Adverse Events as a Measure of Safety and Tolerability, Phase II | Pruritus | 7 participants |
| Phase I Participants (10 mg/15 mg Lenalidomide) | Incidence of Non-Serious Adverse Events as a Measure of Safety and Tolerability, Phase II | Dyspnea | 7 participants |
| Phase I Participants (10 mg/15 mg Lenalidomide) | Incidence of Non-Serious Adverse Events as a Measure of Safety and Tolerability, Phase II | Hyponatremia | 7 participants |
| Phase I Participants (10 mg/15 mg Lenalidomide) | Incidence of Non-Serious Adverse Events as a Measure of Safety and Tolerability, Phase II | Insomnia | 6 participants |
| Phase I Participants (10 mg/15 mg Lenalidomide) | Incidence of Non-Serious Adverse Events as a Measure of Safety and Tolerability, Phase II | Abdominal Pain | 6 participants |
| Phase I Participants (10 mg/15 mg Lenalidomide) | Incidence of Non-Serious Adverse Events as a Measure of Safety and Tolerability, Phase II | Dizziness | 6 participants |
| Phase I Participants (10 mg/15 mg Lenalidomide) | Incidence of Non-Serious Adverse Events as a Measure of Safety and Tolerability, Phase II | Hypokalemia | 6 participants |
| Phase I Participants (10 mg/15 mg Lenalidomide) | Incidence of Non-Serious Adverse Events as a Measure of Safety and Tolerability, Phase II | Weight Loss | 6 participants |
| Phase I Participants (10 mg/15 mg Lenalidomide) | Incidence of Non-Serious Adverse Events as a Measure of Safety and Tolerability, Phase II | Anorexia | 5 participants |
| Phase I Participants (10 mg/15 mg Lenalidomide) | Incidence of Non-Serious Adverse Events as a Measure of Safety and Tolerability, Phase II | Erythema | 5 participants |
| Phase I Participants (10 mg/15 mg Lenalidomide) | Incidence of Non-Serious Adverse Events as a Measure of Safety and Tolerability, Phase II | Hypomagnesemia | 5 participants |
| Phase I Participants (10 mg/15 mg Lenalidomide) | Incidence of Non-Serious Adverse Events as a Measure of Safety and Tolerability, Phase II | Allergic Reaction | 5 participants |
| Phase I Participants (10 mg/15 mg Lenalidomide) | Incidence of Non-Serious Adverse Events as a Measure of Safety and Tolerability, Phase II | Chills | 5 participants |
| Phase I Participants (10 mg/15 mg Lenalidomide) | Incidence of Non-Serious Adverse Events as a Measure of Safety and Tolerability, Phase II | Hyperhidrosis | 5 participants |
| Phase I Participants (10 mg/15 mg Lenalidomide) | Incidence of Non-Serious Adverse Events as a Measure of Safety and Tolerability, Phase II | Myalgia | 4 participants |
| Phase I Participants (10 mg/15 mg Lenalidomide) | Incidence of Non-Serious Adverse Events as a Measure of Safety and Tolerability, Phase II | Headache | 4 participants |
| Phase I Participants (10 mg/15 mg Lenalidomide) | Incidence of Non-Serious Adverse Events as a Measure of Safety and Tolerability, Phase II | Mucositis | 4 participants |
| Phase I Participants (10 mg/15 mg Lenalidomide) | Incidence of Non-Serious Adverse Events as a Measure of Safety and Tolerability, Phase II | Hypoglycemia | 4 participants |
Primary
Maximum Tolerated Dose of Lenalidomide Combined With Bortezomib and Rituximab in Phase I Participants
Determination of the maximum tolerated dose (MTD) of lenalidomide combined with bortezomib and rituximab, defined as the highest dose at which ≤1 of 6 patients experiences a dose-limiting toxicity according to the NCI CTCAE v. 4.03. MTD of Lenalidomide was tested, included with 1.3 mg/m2 subcutaneous (D1, 4, 8, 11) bortezomib, 375 mg/m2 (D1, 8, 15 of Cycle 1, D1 on subsequent cycles) rituximab. Three dose limiting toxicities were reported in two patients (grade 4 neutropenia and grade 3 neuropathy, grade 3 rash)
Time frame: Collected from day of first dose to the end of the first treatment cycle, up to 21 days
Population: Includes patients that were enrolled in both lenalidomide dose levels (10 mg PO daily, 15 mg PO daily) in the Phase I portion of the study
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Phase I Participants (10 mg/15 mg Lenalidomide) | Maximum Tolerated Dose of Lenalidomide Combined With Bortezomib and Rituximab in Phase I Participants | 10 mg lenalidomide, orally, daily, day 1-14 |
Secondary
Duration of Response (DoR) of Phase I and Phase II Participants
Measured from the documented beginning of response (CR or PR) to the time of relapse. This is measured in responders per Non-Hodgkin's Lymphoma Revised Response Criteria for Malignant Lymphoma (Cheson et al. 2007.) CR: complete disappearance of detectable clinical evidence of disease and disease-related symptoms; PR: 50% or greater decrease in sum of product of diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses, no increase in size of other nodes, liver or spleen, no new disease sites, patients with CR and persistent morphologic bone marrow involvement. Duration of Response will be examined using time-to-event analysis methods. Kaplan-Meier figures will be generated and the log-rank test will be used to examine differences existing between various levels of stratification.
Time frame: Every 3 months (+/- 2 weeks) after discontinuation of study treatment for 2 years or until documented disease progression
Population: All participants that received study treatment that were responders (achieved a PR or better)
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Phase I Participants (10 mg/15 mg Lenalidomide) | Duration of Response (DoR) of Phase I and Phase II Participants | 25.72 months |
| Phase II Participants (10 mg Lenalidomide) | Duration of Response (DoR) of Phase I and Phase II Participants | 17.81 months |
Secondary
Duration of Response (DoR) of Previously Treated and Previously Untreated Participants
Measured from the documented beginning of response (CR or PR) to the time of relapse. This is measured in responders per Non-Hodgkin's Lymphoma Revised Response Criteria for Malignant Lymphoma (Cheson et al. 2007.) CR: complete disappearance of detectable clinical evidence of disease and disease-related symptoms; PR: 50% or greater decrease in sum of product of diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses, no increase in size of other nodes, liver or spleen, no new disease sites, patients with CR and persistent morphologic bone marrow involvement.
Time frame: Every 3 months (+/- 2 weeks) after discontinuation of study treatment for 2 years or until documented disease progression
Population: All participants that received study treatment that were responders (achieved a PR or better)
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Phase I Participants (10 mg/15 mg Lenalidomide) | Duration of Response (DoR) of Previously Treated and Previously Untreated Participants | 17.94 months |
| Phase II Participants (10 mg Lenalidomide) | Duration of Response (DoR) of Previously Treated and Previously Untreated Participants | 21.09 months |
Secondary
Overall Response Rate (ORR) of Phase I and Phase II Participants
Response to treatment (Complete Response (CR) or Partial Response (PR)) determined using Non-Hodgkin's Lymphoma Revised Response Criteria for Malignant Lymphoma (Cheson et al. 2007.) CR: complete disappearance of all detectable clinical evidence of disease and disease-related symptoms; PR: 50% or greater decrease in sum of the product of the diameters (SPD) of up to 6 of the largest dominant nodes or extranodal masses, no increase in the size of other nodes, liver or spleen, no new sites of disease, patients who achieve CR but have persistent morphologic bone marrow involvement; Stable Disease (SD): failing to attain PR or CR, but not fulfilling criteria for progressive disease; Progressive Disease (PD)/Relapse: appearance of new lesions more than 1.5 cm in any axis, 50% or greater increase from nadir SPD of any previously involved sites, 50% or greater increase in the longest diameter of any single previously identified node or extranodal mass more than 1 cm in short axis.
Time frame: Every 6 weeks until treatment discontinuation then every 3 months thereafter, projected average 24 months
Population: The efficacy evaluable population (all participants who have received any study treatment)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Phase I Participants (10 mg/15 mg Lenalidomide) | Overall Response Rate (ORR) of Phase I and Phase II Participants | 12 Participants |
| Phase II Participants (10 mg Lenalidomide) | Overall Response Rate (ORR) of Phase I and Phase II Participants | 21 Participants |
Secondary
Overall Response Rate (ORR) of Previously Treated and Previously Untreated Participants
Response to treatment (Complete Response (CR) or Partial Response (PR)) determined using Non-Hodgkin's Lymphoma Revised Response Criteria for Malignant Lymphoma (Cheson et al. 2007.) CR: complete disappearance of all detectable clinical evidence of disease and disease-related symptoms; PR: 50% or greater decrease in sum of the product of the diameters (SPD) of up to 6 of the largest dominant nodes or extranodal masses, no increase in the size of other nodes, liver or spleen, no new sites of disease, patients who achieve CR but have persistent morphologic bone marrow involvement; Stable Disease (SD): failing to attain PR or CR, but not fulfilling criteria for progressive disease; Progressive Disease (PD)/Relapse: appearance of new lesions more than 1.5 cm in any axis, 50% or greater increase from nadir SPD of any previously involved sites, 50% or greater increase in the longest diameter of any single previously identified node or extranodal mass more than 1 cm in short axis.
Time frame: Every 6 weeks until treatment discontinuation then every 3 months thereafter, projected average 24 months
Population: The efficacy evaluable population (all participants who have received any study treatment)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Phase I Participants (10 mg/15 mg Lenalidomide) | Overall Response Rate (ORR) of Previously Treated and Previously Untreated Participants | 8 Participants |
| Phase II Participants (10 mg Lenalidomide) | Overall Response Rate (ORR) of Previously Treated and Previously Untreated Participants | 25 Participants |
Secondary
Overall Survival of Phase I and Phase II Participants
Defined as the date of study entry to the date of death. Overall Survival will be examined using time-to-event analysis methods. Kaplan-Meier figures will be generated and the log-rank test will be used to examine differences existing between various levels of stratification
Time frame: Every 3 months (+/- 2 weeks) after discontinuation of study treatment for 2 years, then every 6 months after documented disease progression
Population: all participants that received study treatment
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Phase I Participants (10 mg/15 mg Lenalidomide) | Overall Survival of Phase I and Phase II Participants | 51.45 months |
| Phase II Participants (10 mg Lenalidomide) | Overall Survival of Phase I and Phase II Participants | 35.35 months |
Secondary
Overall Survival of Previously Treated and Previously Untreated Participants
Defined as the date of study entry to the date of death. Overall Survival will be examined using time-to-event analysis methods. Kaplan-Meier figures will be generated and the log-rank test will be used to examine differences existing between various levels of stratification
Time frame: Every 3 months (+/- 2 weeks) after discontinuation of study treatment for 2 years, then every 6 months after documented disease progression
Population: all participants that received study treatment
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Phase I Participants (10 mg/15 mg Lenalidomide) | Overall Survival of Previously Treated and Previously Untreated Participants | 28.4189 months |
| Phase II Participants (10 mg Lenalidomide) | Overall Survival of Previously Treated and Previously Untreated Participants | 71.2608 months |
Secondary
Progression Free Survival (PFS) of Phase I and Phase II Participants
Defined as the time from entry onto study until lymphoma progression or death from any cause. Progression Free Survival will be examined using time-to-event analysis methods. Kaplan-Meier figures will be generated and the log-rank test will be used to examine differences existing between various levels of stratification.
Time frame: Every 3 months (+/- 2 weeks) after discontinuation of study treatment for 2 years, then every 6 months after documented disease progression
Population: All participants that received study treatment
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Phase I Participants (10 mg/15 mg Lenalidomide) | Progression Free Survival (PFS) of Phase I and Phase II Participants | 27.70 months |
| Phase II Participants (10 mg Lenalidomide) | Progression Free Survival (PFS) of Phase I and Phase II Participants | 19.35 months |
Secondary
Progression Free Survival (PFS) of Previously Treated and Previously Untreated Participants
Defined as the time from entry onto study until lymphoma progression or death from any cause. Progression Free Survival will be examined using time-to-event analysis methods. Kaplan-Meier figures will be generated and the log-rank test will be used to examine differences existing between various levels of stratification.
Time frame: Every 3 months (+/- 2 weeks) after discontinuation of study treatment for 2 years, then every 6 months after documented disease progression
Population: All participants that received study treatment
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Phase I Participants (10 mg/15 mg Lenalidomide) | Progression Free Survival (PFS) of Previously Treated and Previously Untreated Participants | 12.4517 months |
| Phase II Participants (10 mg Lenalidomide) | Progression Free Survival (PFS) of Previously Treated and Previously Untreated Participants | 25.2649 months |
Secondary
Time to Best Response of Phase I and Phase II Participants
Measured from the time of study entry to the documented beginning of response (CR or PR). This is measured in responders per Non-Hodgkin's Lymphoma Revised Response Criteria for Malignant Lymphoma (Cheson et al. 2007.) CR: complete disappearance of detectable clinical evidence of disease and disease-related symptoms; PR: 50% or greater decrease in sum of product of diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses, no increase in size of other nodes, liver or spleen, no new disease sites, patients with CR and persistent morphologic bone marrow involvement. Time to Best Response will be examined using time-to-event analysis methods. Kaplan-Meier figures will be generated and the log-rank test will be used to examine differences existing between various levels of stratification.
Time frame: Every 3 months (+/- 2 weeks) after discontinuation of study treatment for 2 years
Population: All participants that received study treatment that were evaluable for a response assessment (one participant in Phase I and two participants in Phase II were considered unevaluable, discontinuing prior to first post-baseline response assessment)
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Phase I Participants (10 mg/15 mg Lenalidomide) | Time to Best Response of Phase I and Phase II Participants | 63.50 days |
| Phase II Participants (10 mg Lenalidomide) | Time to Best Response of Phase I and Phase II Participants | 71.50 days |
Secondary
Time to Best Response of Previously Treated and Previously Untreated Participants
Measured from the time of study entry to the documented beginning of response (CR or PR). This is measured in responders per Non-Hodgkin's Lymphoma Revised Response Criteria for Malignant Lymphoma (Cheson et al. 2007.) CR: complete disappearance of detectable clinical evidence of disease and disease-related symptoms; PR: 50% or greater decrease in sum of product of diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses, no increase in size of other nodes, liver or spleen, no new disease sites, patients with CR and persistent morphologic bone marrow involvement.
Time frame: Every 3 months (+/- 2 weeks) after discontinuation of study treatment for 2 years
Population: All patients that received study treatment that were evaluable for a response assessment (2 previously untreated participants and 1 previously treated participant were considered unevaluable, discontinuing prior to first post-baseline response assessment)
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Phase I Participants (10 mg/15 mg Lenalidomide) | Time to Best Response of Previously Treated and Previously Untreated Participants | 2.04 months |
| Phase II Participants (10 mg Lenalidomide) | Time to Best Response of Previously Treated and Previously Untreated Participants | 2.37 months |